As a Free StocksGuide user, you can view scores for all 7,082 stocks worldwide.
9 Analysts have issued a Rani Therapeutics Holdings Inc - Ordinary Shares Class A forecast:
9 Analysts have issued a Rani Therapeutics Holdings Inc - Ordinary Shares Class A forecast:
| Sep '25 |
+/-
%
|
||
| Revenue | 1.20 1.20 |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -44 -44 |
14%
14%
|
|
| EBIT (Operating Income) EBIT | -45 -45 |
14%
14%
|
|
| Net Profit | -28 -28 |
1%
1%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Rani Therapeutics Holdings, Inc. operates as a clinical stage bio-therapeutics company providing technologies to enable the development of orally administered biologics. It offers RaniPill capsule, an orally ingestible pill for the administration of a broad range of biologics. The company was founded by Mir Imran on April 6, 2021 and is headquartered in San Jose, CA.
| Head office | United States |
| CEO | Talat Imran |
| Employees | 106 |
| Founded | 2012 |
| Website | www.ranitherapeutics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


